Literature DB >> 28432661

Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes.

Jeffrey W Meeusen1, Leslie J Donato2, Allan S Jaffe2,3.   

Abstract

PURPOSE OF REVIEW: The objective of this review was to summarize evidence gathered for the prognostic value of routine and novel blood lipids and lipoproteins measured in patients with acute coronary syndromes (ACS). RECENT
FINDINGS: Data supports clear association with risk and actionable value for non-high-density lipoprotein (Non-HDL) cholesterol and plasma ceramides in a setting of ACS. The prognostic value and clinical actionability of apolipoprotein B (apoB) and lipoprotein(a) [Lp(a)] in ACS have not been thoroughly tested, while the data for omega-3 fatty acids and oxidized low-density lipoprotein (Ox-LDL) are either untested or more varied. Measuring basic lipids, which should include Non-HDL cholesterol, at the time of presentation for ACS is guideline mandated. Plasma ceramides also provide useful information to guide both treatment decisions and follow-up. Additional studies targeting ACS patients are necessary for apoB, Lp(a), omega-3 fatty acids, and Ox-LDL.

Entities:  

Keywords:  Apolipoprotein B; Ceramides; Lipoprotein(a); Non-HDL cholesterol; Omega-3; Oxidized LDL

Mesh:

Substances:

Year:  2017        PMID: 28432661     DOI: 10.1007/s11886-017-0863-9

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  67 in total

Review 1.  A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids and Coronary Heart Disease Risk.

Authors:  Dominik D Alexander; Paige E Miller; Mary E Van Elswyk; Connye N Kuratko; Lauren C Bylsma
Journal:  Mayo Clin Proc       Date:  2017-01       Impact factor: 7.616

2.  National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.

Authors:  Terry A Jacobson; Matthew K Ito; Kevin C Maki; Carl E Orringer; Harold E Bays; Peter H Jones; James M McKenney; Scott M Grundy; Edward A Gill; Robert A Wild; Don P Wilson; W Virgil Brown
Journal:  J Clin Lipidol       Date:  2014-07-15       Impact factor: 4.766

3.  Ceramide is upregulated and associated with mortality in patients with chronic heart failure.

Authors:  Jingjia Yu; Wei Pan; Ruizheng Shi; Tianlun Yang; Yuanjian Li; Guolong Yu; Yongping Bai; Edward H Schuchman; Xingxuan He; Guogang Zhang
Journal:  Can J Cardiol       Date:  2014-12-11       Impact factor: 5.223

4.  Evidence of free fatty acid interdigitation in stratum corneum model membranes based on ceramide [AP] by deuterium labelling.

Authors:  Annett Schroeter; Mikhail A Kiselev; Thomas Hauss; Silva Dante; Reinhard H H Neubert
Journal:  Biochim Biophys Acta       Date:  2009-08-06

5.  Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction.

Authors:  Meryem Ulku Aydin; Nazif Aygul; Bulent Behlul Altunkeser; Ali Unlu; Alpaslan Taner
Journal:  Atherosclerosis       Date:  2015-02-07       Impact factor: 5.162

6.  Gastric bypass surgery reduces plasma ceramide subspecies and improves insulin sensitivity in severely obese patients.

Authors:  Hazel Huang; Takhar Kasumov; Patrick Gatmaitan; Helen M Heneghan; Sangeeta R Kashyap; Philip R Schauer; Stacy A Brethauer; John P Kirwan
Journal:  Obesity (Silver Spring)       Date:  2011-05-05       Impact factor: 5.002

7.  How soon after myocardial infarction should plasma lipid values be assessed?

Authors:  R E Ryder; T M Hayes; I P Mulligan; J C Kingswood; S Williams; D R Owens
Journal:  Br Med J (Clin Res Ed)       Date:  1984-12-15

8.  Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation.

Authors:  William S Harris; Scott A Sands; Sheryl L Windsor; Hakim A Ali; Tracy L Stevens; Anthony Magalski; Charles B Porter; A Michael Borkon
Journal:  Circulation       Date:  2004-09-07       Impact factor: 29.690

9.  Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events.

Authors:  Samia Mora; Julie E Buring; Paul M Ridker
Journal:  Circulation       Date:  2013-12-17       Impact factor: 29.690

10.  Erythrocyte fatty acid profiles can predict acute non-fatal myocardial infarction.

Authors:  Yongsoon Park; Jeehyun Lim; Jaeung Lee; Soon-gil Kim
Journal:  Br J Nutr       Date:  2009-06-09       Impact factor: 3.718

View more
  6 in total

1.  Altering Sphingolipid Metabolism Attenuates Cell Death and Inflammatory Response After Myocardial Infarction.

Authors:  Yoav Hadas; Adam S Vincek; Elias Youssef; Magdalena M Żak; Elena Chepurko; Nishat Sultana; Mohammad Tofael Kabir Sharkar; Ningning Guo; Rinat Komargodski; Ann Anu Kurian; Keerat Kaur; Ajit Magadum; Anthony Fargnoli; Michael G Katz; Nadia Hossain; Ephraim Kenigsberg; Nicole C Dubois; Eric Schadt; Roger Hajjar; Efrat Eliyahu; Lior Zangi
Journal:  Circulation       Date:  2020-01-29       Impact factor: 29.690

Review 2.  Lipid metabolism in sickness and in health: Emerging regulators of lipotoxicity.

Authors:  Haejin Yoon; Jillian L Shaw; Marcia C Haigis; Anna Greka
Journal:  Mol Cell       Date:  2021-09-16       Impact factor: 19.328

3.  Circulating Ceramide: A New Cardiometabolic Biomarker in Patients With Comorbid Acute Coronary Syndrome and Type 2 Diabetes Mellitus.

Authors:  Ruihua Cao; Zhiyi Fang; Sulei Li; Mengqi Xu; Jibin Zhang; Dong Han; Wenchao Hu; Liqiu Yan; Yabin Wang; Li Fan; Feng Cao
Journal:  Front Physiol       Date:  2020-09-15       Impact factor: 4.566

4.  Effects of Dicyclohexyl Phthalate Exposure on PXR Activation and Lipid Homeostasis in Mice.

Authors:  Yipeng Sui; Zhaojie Meng; Jianzhong Chen; Jingwei Liu; Rebecca Hernandez; Miko B Gonzales; Taesik Gwag; Andrew J Morris; Changcheng Zhou
Journal:  Environ Health Perspect       Date:  2021-12-01       Impact factor: 9.031

5.  Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.

Authors:  Emil Hagström; P Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Nicolas Danchin; Rafael Diaz; Shaun G Goodman; Robert A Harrington; J Wouter Jukema; Evangelos Liberopoulos; Nikolaus Marx; Jennifer McGinniss; Garen Manvelian; Robert Pordy; Michel Scemama; Harvey D White; Andreas M Zeiher; Gregory G Schwartz
Journal:  Circulation       Date:  2022-06-30       Impact factor: 39.918

6.  Sphingolipid composition of circulating extracellular vesicles after myocardial ischemia.

Authors:  J Burrello; V Biemmi; M Dei Cas; M Amongero; S Bolis; E Lazzarini; S Bollini; G Vassalli; R Paroni; L Barile
Journal:  Sci Rep       Date:  2020-09-30       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.